NCT02651987

Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg

Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: Ipsen · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to explore the efficacy and safety of lanreotide Autogel® 120 mg administered every 14 days in subjects with grade 1 or 2, metastatic or locally advanced, unresectable pancreatic or intestinal neuroendocrine tumours (NETs) once they have progressed on the standard dose of lanreotide Autogel® 120 mg every 28 days.

Conditions

• Pancreatic Tumours
• Midgut Neuroendocrine Tumours

Interventions

Type	Name	Description
DRUG	Lanreotide autogel 120 mg

Timeline

• Start date: 2015-12-15
• Primary completion: 2019-10-16
• Completion: 2019-10-24
• First posted: 2016-01-11
• Last updated: 2022-10-03
• Results posted: 2020-12-30

Locations

32 sites across 10 countries: Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Poland, Spain, United Kingdom